ストックスクリーナーアプリを入手
415.21
3.44%
-14.81
アフターアワーズ：
415.21
前日終値:
$430.02
開ける：
$430.45
24時間の取引高:
1.61M
Relative Volume:
1.44
時価総額：
$54.85B
収益：
$3.21B
当期純損益:
$43.57M
株価収益率:
1,726.44
EPS:
0.2405
ネットキャッシュフロー:
$221.36M
1週間 パフォーマンス:
-10.69%
1か月 パフォーマンス:
-6.21%
6か月 パフォーマンス:
+36.58%
1年 パフォーマンス:
+62.26%
1日の値動き範囲:
$412.31
$433.31
1週間の範囲:
$412.31
$479.79
52週間の値動き範囲:
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
名前
Alnylam Pharmaceuticals Inc
セクター
電話
(617) 551-8200
住所
675 WEST KENDALL STREET, CAMBRIDGE, MA
ALNY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
415.21 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.01 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
692.58 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
889.41 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
194.17 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-04 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-08-04 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | 再開されました | Raymond James | Outperform |
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-03-31 | 開始されました | Redburn Atlantic | Buy |
| 2025-03-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-11-12 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-08-16 | アップグレード | Goldman | Neutral → Buy |
| 2024-02-16 | ダウングレード | Goldman | Buy → Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-12-08 | 開始されました | Wells Fargo | Equal Weight |
| 2023-10-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-09-29 | 開始されました | Raymond James | Outperform |
| 2023-05-05 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | 開始されました | SMBC Nikko | Neutral |
| 2023-03-21 | 開始されました | Bernstein | Outperform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Buy |
| 2022-09-09 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-06-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-06-07 | 開始されました | William Blair | Outperform |
| 2022-04-25 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | 開始されました | Citigroup | Buy |
| 2022-02-03 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-01-03 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | アップグレード | Goldman | Neutral → Buy |
| 2021-11-22 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-10-04 | アップグレード | UBS | Neutral → Buy |
| 2021-08-04 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-02-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-02-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-01-25 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | 再開されました | Berenberg | Hold |
| 2020-09-08 | 開始されました | Citigroup | Buy |
| 2020-08-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-04-24 | 再開されました | Evercore ISI | Outperform |
| 2020-03-19 | 開始されました | Berenberg | Buy |
| 2019-12-19 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-11-20 | 開始されました | Oppenheimer | Outperform |
| 2019-11-13 | 開始されました | BofA/Merrill | Buy |
| 2019-05-23 | 再開されました | Goldman | Neutral |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-03-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2019-03-05 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | 開始されました | UBS | Neutral |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-08-13 | 繰り返されました | Stifel | Buy |
| 2018-08-07 | アップグレード | Stifel | Hold → Buy |
| 2018-05-04 | 繰り返されました | Stifel | Hold |
| 2018-03-28 | 開始されました | Evercore ISI | In-line |
すべてを表示
Alnylam Pharmaceuticals Inc (ALNY) 最新ニュース
Thematics Asset Management Purchases New Shares in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Purchased by Investment Management Corp of Ontario - MarketBeat
California Public Employees Retirement System Purchases 10,100 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Trading Down 5.5%Here's Why - MarketBeat
Winslow Capital Management LLC Has $383.95 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 24%? - Yahoo Finance
How (ALNY) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
First Trust Advisors LP Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Is Alnylam Pharmaceuticals a Millionaire Maker? - Finviz
Is Alnylam Pharmaceuticals a Millionaire Maker? - The Motley Fool
Will Board Overhaul And CEO Stock Moves Reshape Alnylam Pharmaceuticals' (ALNY) RNAi Investment Narrative - simplywall.st
Mirabella Financial Services LLP Decreases Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Marshall Wace LLP Sells 30,359 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Schroder Investment Management Group Reduces Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
How Alnylam Pharmaceuticals Inc. stock benefits from tech adoptionJuly 2025 Volume & AI Optimized Trade Strategies - Newser
How Alnylam Pharmaceuticals Inc. (DUL) stock reacts to fiscal policiesMarket Sentiment Review & Risk Controlled Daily Trade Plans - Newser
Dodge & Cox Cuts Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Is Alnylam Pharmaceuticals Inc. (DUL) stock a fit for income portfoliosInsider Buying & Short-Term Trading Alerts - Newser
Is Alnylam Pharmaceuticals Inc. (DUL) stock trading at attractive multiples2025 Market Sentiment & Community Driven Trade Alerts - Newser
Do Alnylam Pharmaceuticals’ (ALNY) Board Moves Quietly Reframe Its Management Incentives and Risk Profile? - Yahoo Finance
Can Alnylam Pharmaceuticals Inc. (DUL) stock sustain institutional flowsPrice Action & Risk Controlled Daily Trade Plans - Newser
What hedge fund activity signals for Alnylam Pharmaceuticals Inc. stock2025 Market Trends & Weekly Watchlist for Hot Stocks - Newser
What dividend safety rating applies to Alnylam Pharmaceuticals Inc. (DUL) stockJuly 2025 WrapUp & Daily Profit Focused Stock Screening - Newser
Alnylam Pharmaceuticals (ALNY): Is the Stock’s Recent Surge Justified by Its Valuation? - simplywall.st
Will Alnylam Pharmaceuticals Inc. stock benefit from commodity pricesPortfolio Performance Report & Stock Market Timing Techniques - Newser
Is Alnylam Pharmaceuticals Inc. (DUL) stock prepared for digital transition2025 Price Targets & Low Risk Entry Point Tips - Newser
1832 Asset Management L.P. Raises Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam announces board changes, appoints Stuart Arbuckle as director By Investing.com - Investing.com Nigeria
Alnylam Pharmaceuticals Announces Changes to Board of Directors - PharmiWeb.com
Alnylam Pharmaceuticals announces changes to board of directors - marketscreener.com
Alnylam announces board changes, appoints Stuart Arbuckle as director - Investing.com
Panagora Asset Management Inc. Trims Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Quadrature Capital Ltd Trims Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Will Alnylam Pharmaceuticals Inc. (DUL) stock boost dividends furtherJuly 2025 Macro Moves & Free Expert Verified Stock Movement Alerts - Newser
Will Alnylam Pharmaceuticals Inc. (DUL) stock benefit from mergersTrend Reversal & Risk Adjusted Buy/Sell Alerts - Newser
Alnylam Pharma, Atour Lifestyle, MongoDB Among These 10 Stocks Worth Watching - Investor's Business Daily
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years - Benzinga
Options Movement At Alnylam Pharmaceuticals: Yvonne Greenstreet Exercises Worth $1.72M - Benzinga
West Family Investments Inc. Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Hsbc Holdings PLC Boosts Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Can Alnylam Pharmaceuticals Inc. (DUL) stock sustain revenue momentumMarket Movement Recap & AI Powered Market Entry Strategies - Newser
Is Alnylam Pharmaceuticals Inc. (DUL) stock good for wealth creationJuly 2025 Catalysts & High Accuracy Swing Trade Signals - Newser
CRH, Vertiv, Ares, Alnylam Could Be Added to S&P 500 Friday in Rebalancing - Barron's
Spotlight On Alnylam Pharmaceuticals And 2 Other Stocks Possibly Trading Below Fair Value - Yahoo Finance
2,032,680 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Norges Bank - MarketBeat
Advisors Asset Management Inc. Reduces Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Skandinaviska Enskilda Banken AB publ - MarketBeat
Loomis Sayles & Co. L P Sells 10,750 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Korea Investment CORP Acquires 5,096 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals Inc (ALNY) 財務データ
収益
当期純利益
現金流量
EPS
1.26%
大文字化:
|
ボリューム (24 時間):